Development of Therapeutic Vaccines for Ovarian Cancer
Stephanie Chow1, Jonathan S Berek1, Oliver Dorigo1
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Abstract:
Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding knowledge of ovarian cancer immunology has allowed the development of therapies that generate systemic anti-tumor immune responses. Current immunotherapeutic strategies include immune checkpoint blockade, cellular therapies, and cancer vaccines. Vaccine-based therapies are designed to induce both adaptive and innate immune responses directed against ovarian cancer associated antigens. Tumor-specific effector cells, in particular cytotoxic T cells, are activated to recognize and eliminate ovarian cancer cells. Vaccines for ovarian cancer have been studied in various clinical trials over the last three decades. Despite evidence of vaccine-induced humoral and cellular immune responses, the majority of vaccines have not shown significant anti-tumor efficacy. Recently, improved vaccine development using dendritic cells or synthetic platforms for antigen presentation have shown promising clinical benefits in patients with ovarian cancer. In this review, we provide an overview of therapeutic vaccine development in ovarian cancer, discuss proposed mechanisms of action, and summarize the current clinical experience.
Insights
Therapeutic cancer vaccines for ovarian cancer aim to boost immune responses against tumors. Recent advancements in vaccine platforms show promise for improved clinical benefits in patients.
Area of Science:
- Oncology
- Immunology
- Gynecologic Oncology
Background:
- Ovarian cancer is a leading cause of gynecologic cancer deaths.
- Advances in understanding ovarian cancer immunology enable new immunotherapies.
- Current strategies include immune checkpoint blockade, cellular therapies, and cancer vaccines.
Purpose of the Study:
- To review therapeutic vaccine development for ovarian cancer.
- To discuss proposed mechanisms of action for these vaccines.
- To summarize current clinical experiences with ovarian cancer vaccines.
Main Methods:
- Review of clinical trials and scientific literature on ovarian cancer vaccines.
- Analysis of vaccine-induced immune responses (humoral and cellular).
- Evaluation of novel vaccine platforms, including dendritic cell and synthetic antigen presentation systems.
Main Results:
- Ovarian cancer vaccines aim to elicit systemic anti-tumor immunity.
- Vaccines activate tumor-specific effector cells like cytotoxic T cells.
- Despite historical challenges, recent vaccine platforms show promising clinical benefits.
Conclusions:
- Therapeutic vaccines represent a key strategy in ovarian cancer immunotherapy.
- Improved vaccine platforms are enhancing efficacy and clinical outcomes.
- Continued research into vaccine mechanisms and clinical application is crucial for advancing ovarian cancer treatment.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...